Literature DB >> 26812695

Global rank tests for multiple, possibly censored, outcomes.

Ritesh Ramchandani1, David A Schoenfeld2,3, Dianne M Finkelstein2,3.   

Abstract

Clinical trials often collect multiple outcomes on each patient, as the treatment may be expected to affect the patient on many dimensions. For example, a treatment for a neurological disease such as ALS is intended to impact several dimensions of neurological function as well as survival. The assessment of treatment on the basis of multiple outcomes is challenging, both in terms of selecting a test and interpreting the results. Several global tests have been proposed, and we provide a general approach to selecting and executing a global test. The tests require minimal parametric assumptions, are flexible about weighting of the various outcomes, and are appropriate even when some or all of the outcomes are censored. The test we propose is based on a simple scoring mechanism applied to each pair of subjects for each endpoint. The pairwise scores are then reduced to a summary score, and a rank-sum test is applied to the summary scores. This can be seen as a generalization of previously proposed nonparametric global tests (e.g., O'Brien, 1984). We discuss the choice of optimal weighting schemes based on power and relative importance of the outcomes. As the optimal weights are generally unknown in practice, we also propose an adaptive weighting scheme and evaluate its performance in simulations. We apply the methods to analyze the impact of a treatment on neurological function and death in an ALS trial.
© 2016, The International Biometric Society.

Entities:  

Keywords:  ALS; Global test; Multiple endpoints; Nonparametric; Rank-sum; U-statistic

Mesh:

Year:  2016        PMID: 26812695      PMCID: PMC4960007          DOI: 10.1111/biom.12475

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  22 in total

1.  Analysis of a clinical trial involving a combined mortality and adherence dependent interval censored endpoint.

Authors:  L A Moyé; B R Davis; C M Hawkins
Journal:  Stat Med       Date:  1992-09-30       Impact factor: 2.373

2.  A global rank end point for clinical trials in acute heart failure.

Authors:  G Michael Felker; Alan S Maisel
Journal:  Circ Heart Fail       Date:  2010-09       Impact factor: 8.790

3.  Adjusting O'Brien's test to control type I error for the generalized nonparametric Behrens-Fisher problem.

Authors:  Peng Huang; Barbara C Tilley; Robert F Woolson; Stuart Lipsitz
Journal:  Biometrics       Date:  2005-06       Impact factor: 2.571

4.  Self-designing clinical trials.

Authors:  L D Fisher
Journal:  Stat Med       Date:  1998-07-30       Impact factor: 2.373

5.  Surrogate endpoints in clinical trials: cardiovascular diseases.

Authors:  J Wittes; E Lakatos; J Probstfield
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

6.  The analysis of multiple endpoints in clinical trials.

Authors:  S J Pocock; N L Geller; A A Tsiatis
Journal:  Biometrics       Date:  1987-09       Impact factor: 2.571

7.  Combining censored and uncensored data in a U-statistic: design and sample size implications for cell therapy research.

Authors:  Lemuel A Moyé; Dejian Lai; Kaiyan Jing; Mary Sarah Baraniuk; Minjung Kwak; Marc S Penn; Colon O Wu
Journal:  Int J Biostat       Date:  2011-07-22       Impact factor: 0.968

8.  Comparison of analysis approaches for phase III clinical trials in amyotrophic lateral sclerosis.

Authors:  Brian C Healy; David Schoenfeld
Journal:  Muscle Nerve       Date:  2012-10       Impact factor: 3.217

9.  A rank-based sample size method for multiple outcomes in clinical trials.

Authors:  Peng Huang; Robert F Woolson; Peter C O'Brien
Journal:  Stat Med       Date:  2008-07-20       Impact factor: 2.373

10.  A hybrid procedure for detecting global treatment effects in multivariate clinical trials: theory and applications to fMRI studies.

Authors:  Giorgos Minas; Fabio Rigat; Thomas E Nichols; John A D Aston; Nigel Stallard
Journal:  Stat Med       Date:  2011-12-15       Impact factor: 2.373

View more
  8 in total

1.  An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.

Authors:  Roland A Matsouaka; Aneesh B Singhal; Rebecca A Betensky
Journal:  Stat Methods Med Res       Date:  2016-12-29       Impact factor: 3.021

2.  Multistate modeling and simulation of patient trajectories after allogeneic hematopoietic stem cell transplantation to inform drug development.

Authors:  David A James; Jennifer Ng; Jiawei Wei; Marc Vandemeulebroecke
Journal:  Biom J       Date:  2018-09-17       Impact factor: 2.207

3.  A framework for considering the risk-benefit trade-off in designing noninferiority trials using composite outcome approaches.

Authors:  Grace Montepiedra; Ritesh Ramchandani; Sachiko Miyahara; Soyeon Kim
Journal:  Stat Med       Date:  2020-10-26       Impact factor: 2.373

4.  Applying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical Trials.

Authors:  Sachiko Miyahara; Ritesh Ramchandani; Soyeon Kim; Scott R Evans; Amita Gupta; Susan Swindells; Richard E Chaisson; Grace Montepiedra
Journal:  Clin Infect Dis       Date:  2020-02-03       Impact factor: 9.079

5.  Sample size formula for general win ratio analysis.

Authors:  Lu Mao; KyungMann Kim; Xinran Miao
Journal:  Biometrics       Date:  2021-06-08       Impact factor: 1.701

6.  Cross-validation of optimized composites for preclinical Alzheimer's disease.

Authors:  Michael C Donohue; Chung-Kai Sun; Rema Raman; Philip S Insel; Paul S Aisen
Journal:  Alzheimers Dement (N Y)       Date:  2017-01

Review 7.  Aortic Stenosis and Heart Failure: Disease Ascertainment and Statistical Considerations for Clinical Trials.

Authors:  Ernest Spitzer; Rebecca T Hahn; Philippe Pibarot; Ton de Vries; Jeroen J Bax; Martin B Leon; Nicolas M Van Mieghem
Journal:  Card Fail Rev       Date:  2019-05-24

8.  Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.

Authors:  William Camu; Marius Mickunas; Jean-Luc Veyrune; Christine Payan; Cecilia Garlanda; Massimo Locati; Raul Juntas-Morales; Nicolas Pageot; Andrea Malaspina; Ulf Andreasson; Janine Kirby; Carey Suehs; Safa Saker; Christophe Masseguin; John De Vos; Henrik Zetterberg; Pamela J Shaw; Ammar Al-Chalabi; P Nigel Leigh; Timothy Tree; Gilbert Bensimon
Journal:  EBioMedicine       Date:  2020-07-07       Impact factor: 8.143

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.